✦ LIBER ✦

Decreased myelotoxicity of gemcitabine and cisplatin in advanced non-small cell lung cancer (NSCLC) with cisplatin infusion on day 15

✍ Scribed by Cortesi, E.; Ramponi, S.; Corona, M.; Moscetti, L.; Grifalchi, F.; Oliva, A.; Lembo, A.; Gasperoni, S.; Padovani, A.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment of advanced non-small cell lun

✍ Almodovar, M; Dionisio, J; Matias, D; Duro da Costa, J 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 105 KB

67 Phase II activity of gemcitabine + ci

✍ Gonzalez-Barón, M.; Gracia, M.; García Girón, C.; Lizón, J.; Constenla, M.; Aguí 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 145 KB

Gemcitabine, Ifosfamide and Cisplatin (G

✍ De las Peñas, R. 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 84 KB

Pharmacology of the paclitaxel–cisplatin

✍ J. R. Kroep; E. F. Smit; G. Giaccone; K. Van der Born; J. H. Beijnen; C. J. Van 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 248 KB

P-568 Treatment of advanced non small ce

✍ Rubio, I.; Muñoz, A.; López-Vivanco, G.; Barceló, R.; Lopez-Argumedo, G.; Carrer 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 139 KB

Phase I study of gemcitabine (GEM) and c

📂 Article 📅 1994 🏛 Elsevier Science 🌐 English ⚖ 150 KB